A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)

Sponsored by Lundbeck Inc.

Phase Quota
Phase 4

The purpose of the study is to evaluate the change in visual fields by means of automated static perimetry and to evaluate the change in retinal structure by means of spectral domain optical coherence tomography (SD-OCT) in adult patients with refractory complex partial seizures (CPS) being treated with vigabatrin (Sabril®)

Study Start Date: December 2010

Estimated Completion Date: May 2015

Specialties: Neurology: Neuro/Psych pharmacology,Seizure Ophthalmology: Neuro-Ophthalmology,Retina Pharmacy: Adverse Drug Reactions,Neuro/Psych pharmacology


  • Drug: Sabril
  • Drug: Vigabatrin

Inclusion criteria

  • The patient speaks English or Spanish.
  • The patient has had no prior exposure to Sabril.
  • To begin Sabril therapy for the treatment of CPS.
  • Male or female ≥18 years of age.
  • The patient has refractory CPS:
    • The patient has complex partial epilepsy of more than 1 year duration and no other seizure type within the past year except for partial seizures secondarily generalized.
    • The patient has failed because of lack of efficacy 3 or more prior or concurrent treatment trials including 3 or more anti-epileptic drugs (AEDs) of differing pharmacologic mechanisms administered as monotherapy or polytherapy.
    • The patient is taking at least 1 AED. A vagal nerve stimulator is not counted as an AED.
    • The patient reports an average of 2 or more seizures per month averaged over the prior 3 months.
  • The patient is deemed by the treating neurologist and ophthalmologist to be able to reliably complete perimetry testing.
  • The initial (Visit 1) SD-OCT and static perimetry readings tests must be performed and assessed for technical adequacy by the SD-OCT and perimetry central readers prior to the first dose of Sabril. The initial (Visit 1) tangent corner test must be performed prior to the first dose of Sabril.

Exclusion criteria

  • Prior exposure to Sabril.
  • Pre-existing ocular or neurological disease that might affect bilateral visual fields or interfere with perimetry (e.g., aphakia, visually significant cataract, glaucoma, diabetes mellitus, ischemic optic neuropathy, multiple sclerosis). Patients with stable visual field defects from CNS lesions (e.g., epilepsy surgery more than 6 months prior to receiving Sabril) may be enrolled.
  • Concurrent exposure to medications with known or suspected retinal or optic nerve toxicity.
  • Concurrent use of an investigational agent or device or such use within 30 days of entering the study.
  • Concurrent use of the ketogenic or similar diet.
  • For any reason, the patient is considered by the investigator to be an unsuitable candidate for the study.

Study Locations And Contact Information

  • Oregon Health and Science University, Portland Oregon
  • Idaho Comprehensive Epilepsy Center, Boise Idaho
  • Thomas Jefferson University, Philadelphia Pennsylvania
  • Neuroscience Spine Institute, Charlotte North Carolina
  • Columbia University Medical Center, New York New York
  • California Pacific Medical Center, San Francisco California
  • CNMRI, Dover Delaware
  • University of Texas Health Science Center, San Antonio Texas
  • Aurora St Lukes Medical Center, Milwaukee Wisconsin
  • Minnesota Epilepsy Group PA, St. Paul Minnesota
  • Medical University of South Carolina, Charleston South Carolina
  • University of Kentucky Lexington, Lexington Kentucky
  • DartmouthHitchcock Medical Center, Lebanon New Hampshire
  • OSF Saint Francis Medical Center, Peoria Illinois
  • Yale Medical Center, New Haven Connecticut
  • University of Texas, Houston Texas
  • Covenant Medical Group, Lubbock Texas
  • Aurora BayCare Medical Center, Green Bay Wisconsin
  • Ochsner Clinic Foundation, New Orleans Louisiana
  • Sunrise Clinical Research Group, Hollywood Florida
  • Peachtree Neurological Clinic, Atlanta Georgia
  • University of South Florida, Tampa Florida

Feature this Clinical Trial

Get your trial in front of 1000s of physicians and patients.
Visit to find out how you can feature this clinical trial.